A Phase II Study of Efficacy and Safety of the MEK Inhibitor Tunlametinib in Patients with Advanced NRAS-mutant Melanoma
EUROPEAN JOURNAL OF CANCER(2024)
关键词
Melanoma,NRAS mutation,MEK inhibitor,tunlametinib
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要